Adverts

Open Access Articles- Top Results for Vestipitant

Vestipitant

</th></tr>
Vestipitant
220px
Systematic (IUPAC) name
(2S)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methylpiperazine-1-carboxamide
Clinical data
Identifiers
334476-64-1 7pxY
None
PubChem CID 9832383
UNII S052TOI9BI 7pxN
ChEMBL CHEMBL522987 7pxN
Chemical data
Formula C23H21F10N3O
545.416 g/mol
 14pxN (what is this?)  (verify)

Vestipitant is a drug developed by GlaxoSmithKline which acts as a selective antagonist for the NK1 receptor. It is under development as a potential antiemetic and anxiolytic drug,[1][2] and as a treatment for tinnitus[3] and insomnia.[4]

See also

References

  1. ^ Reddy, GK; Gralla, RJ; Hesketh, PJ (2006). "Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis". Supportive cancer therapy 3 (3): 140–2. PMID 18632487. doi:10.3816/SCT.2006.n.011. 
  2. ^ Brocco, M; Dekeyne, A; Mannoury La Cour, C; Touzard, M; Girardon, S; Veiga, S; De Nanteuil, G; Dejong, TR et al. (2008). "Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents". European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 18 (10): 729–50. PMID 18657401. doi:10.1016/j.euroneuro.2008.06.002. 
  3. ^ Clinical trial number NCT00394056 for "Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss" at ClinicalTrials.gov
  4. ^ Ratti, E et al. (December 2013). "Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia.". Sleep (2013) 36 (12): 1823–30. PMC 3825431. PMID 24293756. doi:10.5665/sleep.3208. 


Lua error in package.lua at line 80: module 'Module:Buffer' not found. Lua error in package.lua at line 80: module 'Module:Buffer' not found.